[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586484":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":27,"locations":33,"responsibleParty":46,"collaborators":31,"id":48,"slug":31,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":31,"eligibilityCriteria":52,"healthyVolunteers":49,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":31,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":31,"overallStatus":35,"whyStopped":31,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Ain Shams University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Burn ICU patients","EXPERIMENTAL","Interleukin 6 and procalcitonin will be sampled for all patients on days 1, 3, 7, and 10. Treatment plan will be initiated to all patients according to the burn ICU protocol.",[13],"Diagnostic Test: Interleukin 6",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","Interleukin 6","Interleukin 6 and procalcitonin will be sampled for all patients on days 1, 3, 7, and 10",[9],[21],"Procalcitonin",[23],{"name":24,"affiliation":25,"role":26},"Ahmed H Elsayed, M.B.B.CH","Anaesthesia, intensive care, and pain management resident Ain Shams University","PRINCIPAL_INVESTIGATOR",[28],{"name":24,"role":29,"phone":30,"phoneExt":31,"email":32},"CONTACT","+201016305451",null,"AhmedHanyAbdelfatah@med.asu.edu.eg",[34],{"facility":5,"status":35,"city":36,"state":31,"zip":31,"country":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"RECRUITING","Cairo","Egypt",{"type":39,"coordinates":40},"Point",[41,42],31.24967,30.06263,{"lat":42,"lon":41},[45],{"name":24,"role":29,"phone":30,"phoneExt":31,"email":32},{"type":47,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100586484",false,"NCT06915974","Comparison Between Interleukin 6 and Procalcitonin in Detecting Sepsis and Incidence of Mortality in Burn ICU Patients","Inclusion Criteria:\n\n* Patients with acute burn admitted to burn ICU within 24 hours from the burn incidence.\n* patients with burn percentage of 25% to 50% of total body surface area\n* patients with second to third degree burns\n* ASA 1 and ASA 2 patients\n\nExclusion Criteria:\n\n* Burn percentage more than 50% or less than 25% of total body surface area\n* Having autoimmune diseases\n* Cancer patients\n* ASA 3 and ASA 4 patients","ALL","25 Years","60 Years",{"count":57,"type":58},70,"ESTIMATED","INTERVENTIONAL",[61],"NA","The investigators will compare the efficacy of Interleukin-6 (IL-6) as a better indicator than procalcitonin in burn patients with sepsis or septic shock regarding success of treatment and early ICU discharge.",[64,65,66,67],"Burns","Sepsis","Septic Shock","Death","2025-04-04",{"date":70,"type":71},"2025-04-08","ACTUAL",{"date":73,"type":71},"2025-01-10",{"date":75,"type":58},"2025-07-10",{"name":5,"class":6},1]